6 results
8-K
EX-99.1
FOXO
FOXO Technologies Inc - Ordinary Shares
10 Aug 23
FOXO Technologies™ Announces Second Quarter 2023 Financial Results
4:05pm
more R&D and market research.
Basic and diluted earnings per share increased to $(0.49) and $(0.83) for the three and six months ended June 30, 2023
425
FOXO
FOXO Technologies Inc - Ordinary Shares
18 Aug 22
Business combination disclosure
6:38pm
traditional online small term. So it’s the small term is easy to kind of get the lift going while we do some finishing R&D and kind of get this whole machine up
425
FOXO
FOXO Technologies Inc - Ordinary Shares
6 Jun 22
Business combination disclosure
9:28pm
us in thinking about some of the R&D and the commercialization timeline and the key hurdles that we need to approve up where we can use these saliva … of finishing R&D projects underway that are necessary to complete before we can bring these saliva-based epigenetic biomarkers into market for underwriting
425
FOXO
FOXO Technologies Inc - Ordinary Shares
8 Apr 22
Business combination disclosure
6:56pm
and are very relevant to all cause mortality.
So we know the science works. So now we’re in this process of refining it. We’ve got some incredible R&D underway
425
EX-99.1
FOXO
FOXO Technologies Inc - Ordinary Shares
25 Feb 22
Business combination disclosure
6:09am
epigenetic biomarker R&D Build technology stack to support operations Acquire life insurance company: FOXO Life Insurance Company Preparation We … -- No / Limited Balance Sheet -- High R&D Expenditures -- Exclusive IP -- Regulatory Oversight -- HSCM Public InsurTech Index
FOXO INVESTOR DECK 2022 Page
8-K
EX-99.1
du0ay 0gcl
25 Feb 22
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
12:00am
- Prev
- 1
- Next